arrow
B

Benoist Chibaudel

franco-british institute
H指数:41
被引数:8,173

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating longitudinal toxicity and adverse event in cetuximab-treated metastatic colorectal cancer: a pooled analysis from 1,302 patients in ARCAD database

评估西妥昔单抗治疗转移性结直肠癌的纵向毒性和不良事件:一项来自ARCAD数据库中1,302例患者的合并分析

2026-08-240
PRE
Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-derived external control arms

转移性结直肠癌随机试验中基于ARCAD衍生外部对照臂的总体生存期可重复性

2026-08-220
PRE
Diagnostic Challenges of Tumor Tissue and Circulating Microsatellite Status Assessment in Metastatic Colorectal Cancer and Their Impact on Access to Immunotherapy: A Real-World Retrospective Study

转移性结直肠癌中肿瘤组织与循环微卫星状态评估的诊断挑战及其对免疫治疗可及性的影响:一项真实世界回顾性研究

Cancers
IF4.4
2026-06-230
OA
Prognostic value of liver metastases and KRAS mutations in patients with metastatic colorectal cancer: A pooled analysis of third-line placebo-controlled trials from the ARCAD CRC database

肝转移和KRAS突变在转移性结直肠癌患者中的预后价值:基于ARCAD CRC数据库中第三线安慰剂对照试验的合并分析

2026-05-250
PRE
STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer

STRATEGIC-1:多线、随机、开放标签的GERCOR-PRODIGE-39 III期临床试验,用于不可切除的RAS/BRAF野生型转移性结直肠癌

2026-04-140
OAAI
Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES)

新辅助帕博利珠单抗联合观察等待策略治疗局部MSI/dMMR结直肠癌:一项随机GERCOR 109 – PRODIGE 84期II临床试验(PREMICES)的研究方案

2025-11-220
OAAI
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study

错配修复缺陷型转移性结直肠癌患者中肌少症、GDF-15与纳武利尤单抗联合伊匹木单抗疗效的相互作用:GERCOR NIPICOL II期研究的最终生存分析

2025-05-190
OA
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma

循环肿瘤DNA强烈预测化疗联合免疫检查点抑制剂在晚期胃食管腺癌患者中的疗效

2025-04-240
OA
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
2025-03-010
PRE
Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis

肿瘤和淋巴结分期对III期结直肠癌患者辅助奥沙利铂为基础化疗疗效的影响:一项ACCENT合并分析

2025-03-010
OAAI
Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort
2024-12-010
PRE
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
2024-11-121
OA
G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study

G-CSF二级预防在经曲氟尿苷/ tipiracil(FTD/TPI)治疗的转移性结直肠癌(mCRC)患者(pts)中的应用:GERCOR LONGBOARD研究

2024-09-010
PRE
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis

经全身治疗的结直肠癌肝转移的预后价值: ARCAD汇总分析

2024-08-011
PRE
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation
2024-03-013
PRE
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
2024-02-240
OA
Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial
2023-12-013
OA
Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database (vol 178, pg 162, 2023)
2023-11-010
OA